Insider Transactions in Q2 2021 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,777
-100.0%
|
$108,397
$61.61 P/Share
|
|
Jun 21
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+50.0%
|
$90,627
$51.51 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
48,493
-75.79%
|
$2,909,580
$60.11 P/Share
|
|
Jun 18
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,493
+25.97%
|
$2,182,185
$45.08 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,502
-13.91%
|
$150,120
$60.02 P/Share
|
|
Jun 17
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,502
+12.21%
|
$97,578
$39.76 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,853
-57.38%
|
$1,251,180
$60.06 P/Share
|
|
Jun 10
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,853
+36.46%
|
$813,267
$39.76 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,149
-31.58%
|
$428,940
$60.16 P/Share
|
|
Jun 09
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,149
+24.0%
|
$278,811
$39.76 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,675
-30.12%
|
$400,500
$60.07 P/Share
|
|
Jun 08
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,675
+23.15%
|
$260,325
$39.76 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,268
-21.6%
|
$256,080
$60.04 P/Share
|
|
Jun 07
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,268
+17.77%
|
$166,452
$39.76 P/Share
|
|
May 28
2021
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 28
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+1.45%
|
-
|
|
May 28
2021
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+23.35%
|
-
|
|
May 28
2021
|
Paul J Clancy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 28
2021
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+19.05%
|
-
|
|
May 28
2021
|
John Maraganore Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+5.6%
|
-
|
|
May 28
2021
|
Ian T Clark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,686
+25.35%
|
-
|
|
May 14
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,462
-32.44%
|
$190,410
$55.41 P/Share
|
|
Apr 20
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,401
-48.18%
|
$792,055
$55.11 P/Share
|
|
Apr 20
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,401
+18.41%
|
$532,837
$37.46 P/Share
|
|
Apr 19
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,210
-17.17%
|
$176,550
$55.16 P/Share
|
|
Apr 19
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,210
+14.65%
|
$112,350
$35.16 P/Share
|
|
Apr 16
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,118
-100.0%
|
$61,490
$55.89 P/Share
|
|
Apr 15
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
991
-46.99%
|
$53,514
$54.0 P/Share
|